Peer-reviewed veterinary case report
Dirlotapide helps obese dogs lose 12-14% body weight safely
By Wren, J A et al.·Published in Journal of veterinary pharmacology and therapeutics·2007·Pfizer Inc, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America.
- Species:
- dog
Plain-English summary
A group of 335 obese dogs from various breeds were given either a weight-loss medication called dirlotapide or a placebo to see which helped them lose weight more effectively. The dogs taking dirlotapide lost an average of 11.8% to 14.0% of their body weight over 16 weeks, while those on the placebo only lost about 3.0% to 3.9%. Although some dogs experienced side effects like vomiting, lethargy, and diarrhea, these issues resolved on their own over time. Overall, dirlotapide was found to be safe and effective for helping dogs lose weight and improve their activity levels.
People also search for: dog weight loss medication · dirlotapide for obese dogs · side effects of weight loss drugs in dogs
Abstract
Dirlotapide was evaluated in the management of obesity in dogs in two multicenter, clinical studies in North America. A total of 335 obese dogs of various breeds were randomized to dirlotapide or placebo in a 2:1 ratio. Dirlotapide was administered orally once daily to dogs at an initial dose of 0.05 mg/kg, increased after 14 days to 0.1 (study B, label dose) or 0.2 mg/kg (study A) and then adjusted according to individual weight loss at 28-day intervals. Dogs were examined and weighed, and body condition scores (BCSs) were recorded every 28 days. Study A had three consecutive phases: weight loss (16 weeks, day 0-112); weight management (12 weeks); and post-treatment (8 weeks). Study B had a weight loss phase only. For dirlotapide-treated dogs, mean weight loss by day 112 was 11.8-14.0% compared with 3.0-3.9% for placebo (P = 0.0001). In study A, weight losses for dirlotapide were 19.3% after 12 weeks of weight management and 16.7% (regain of 3.4%) by 8 weeks after dirlotapide was discontinued. In both studies, dogs in both treatments had emesis, lethargy, anorexia, diarrhea, and mildly elevated hepatic transaminase activity, that resolved spontaneously with time. These were experienced more frequently with dirlotapide. Improved activity levels and BCS for >50% dogs were reported with dirlotapide. Dirlotapide was safe and effective in the reduction and management of body weight in obese dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17567518/